Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia

Floris C. Loeff, Kevin Rijs, Willem H. Zoutman, Esther H.M. Egmond, Maarten H. Vermeer, MD PhD, J.H. Frederik Falkenburg, MD PhD, Constantijn J.M. Halkes, MD PhD, Inge Jedema, PhD

Blood (2015) 126 (23): 1435.

https://doi.org/10.1182/blood.V126.23.1435.1435

Published: 2015

Journal Articles

A Polyclonal Population of Piga Mutant CD52 and GPI Anchor Negative T Cells Can Give Early Immune Protection after Alemtuzumab-Based T Cell Depleted Allogeneic Stem Cell Transplantation

Floris C. Loeff, J.H. Frederik Falkenburg, MD PhD, Lois Hageman, Sabrina A.J. Veld, Marian van de Meent, Constantijn J.M. Halkes, MD PhD, Inge Jedema, PhD

Blood (2015) 126 (23): 3134.

https://doi.org/10.1182/blood.V126.23.3134.3134

Published: 2015

Journal Articles

Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants

Sabine Cerny-Reiterer, D.V.M, Katharina Blatt, MSc, Ph.D., Harald Herrmann, M.D., Gregor Eisenwort, M.D., Ph.D, Susanne Herndlhofer, Heinz Sill, M.D., Werner Rabitsch, MD, Christine Mannhalter, M.D., Alexander Hauswirth, M.D., Wolfgang R Sperr, M.D., Ulrich Jaeger, Peter Valent

Blood (2013) 122 (21): 1654.

https://doi.org/10.1182/blood.V122.21.1654.1654

Published: 2013

Journal Articles

Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.

Gregor Hoermann, M.D., Ph.D., Katharina Blatt, MSc, Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Leonhard Müllauer, M.D., Peter Valent, MD, Matthias Mayerhofer, M.D.

Blood (2012) 120 (21): 2866.

https://doi.org/10.1182/blood.V120.21.2866.2866

Published: 2012

Journal Articles

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

Katharina Blatt, M.Sc., Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Susanne Herndlhofer, Wolfgang R. Sperr, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 1728.

https://doi.org/10.1182/blood.V118.21.1728.1728

Published: 2011

Journal Articles

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Marco Montillo, MD, Alessandra Tedeschi, Francesca Ricci, Alfonso Zaccaria, Monica Crugnola, Mauro Spriano, PierAngelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Angelo De Blasio, Eleonora Vismara, Enrica Morra, Valeria Belsito Petrizzi

Blood (2010) 116 (21): 1384.

https://doi.org/10.1182/blood.V116.21.1384.1384

Published: 2010

Journal Articles

Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).

De Padua Silva Leandro, Rima Saliba, Donna McCormick, Grace-Julia Okoroji, Amin Alousi, Paolo Anderlini, Stefan Ciurea, Chitra Hosing, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Naoto Ueno, John McMannis, Richard Champlin, Barbara Pro, Issa F Khouri

Blood (2009) 114 (22): 3213.

https://doi.org/10.1182/blood.V114.22.3213.3213

Published: 2009

Journal Articles

Sustained, Durable Responses with Alemtuzumab in Refractory Angioimmunoblastic T-Cell Lymphoma.

Jennifer E. Amengual, MD, Bruce G. Raphael, MD

Blood (2009) 114 (22): 2730.

https://doi.org/10.1182/blood.V114.22.2730.2730

Published: 2009

Journal Articles

Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.

Seok Jin Kim, MD, PhD, Ary Harryanto Reksodiputro, Ann-Lii Cheng, Tanin Intragumtornchai, MD, Surapol Issaragrisil, MD, Joon Ho Moon, M.D., Jin Seok Kim, M.D., Ph.D., Je-Jung Lee, Jong Ho Won, Won Seog Kim, Yok Lam Kwong, MD

Blood (2009) 114 (22): 5009.

https://doi.org/10.1182/blood.V114.22.5009.5009

Published: 2009

Journal Articles

Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada

Pierre K Isogai, B.Sc, Matthew Cheung, MD, Nicole Mittmann, MSc, PhD

Blood (2008) 112 (11): 2375.

https://doi.org/10.1182/blood.V112.11.2375.2375

Published: 2008

Journal Articles

Alemtuzumab and DHAP (A-DHAP) Is An Effective Salvage Therapy for Peripheral T-Cell Lymphoma, Unspecified: Interim Results of a Phase II Prospective Multicenter Study

Seok Jin Kim, MD, PhD, Kihyun Kim, Byung Soo Kim, Cheolwon Suh, Won Seog Kim

Blood (2008) 112 (11): 5002.

https://doi.org/10.1182/blood.V112.11.5002.5002

Published: 2008

Journal Articles

Emergence of Rituximab-Fludarabine Resistance Is Associated with Changes in CD20 Antigen Expression and Improved Response to Almetuzumab Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Umeer Ashraf, MD, Anjana N. Elefante, PharmD, Raymond Cruz, MD, Paul K. Wallace, PhD, Myron S. Czuczman, MD, Francisco J. Hernandez-llizaliturri, MD

Blood (2007) 110 (11): 2054.

https://doi.org/10.1182/blood.V110.11.2054.2054

Published: 2007

Journal Articles

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102).

Gerard Lozanski, MD, Ben Sanford, MS, Krzysztof Mrozek, MD, PhD, Colin Edwards, PhD, Rebecca Pearson, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2007) 110 (11): 2386.

https://doi.org/10.1182/blood.V110.11.2386.2386

Published: 2007

Journal Articles

Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft- Versus -Host Disease.

David Gomez-Almaguer, MD, Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP, Oscar Gonzalez-Llano, MD, Homero C. Gutierrez-Aguire, MD, Olga G. Cantu-Rodriguez, MD, Jose C. Jaime-Perez, MD, Sergio Giralt, MD

Blood (2007) 110 (11): 2983.

https://doi.org/10.1182/blood.V110.11.2983.2983

Published: 2007

Journal Articles

A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD).

Pierluigi Porcu, MD, Robert A. Baiocchi, MD, Thomas S. Lin, MD, PhD, Kristie A. Blum, MD, Patricia Curtis, RN, Grever R. Michael, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3417.

https://doi.org/10.1182/blood.V110.11.3417.3417

Published: 2007

Journal Articles

Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

C. Schweighofer, M. Ritgen, B. Eichhorst, R. Busch, M. Kneba, M. Hallek, Clemens Wendtner, the German CLL Study Group

Blood (2006) 108 (11): 33.

https://doi.org/10.1182/blood.V108.11.33.33

Published: 2006

Journal Articles

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Alfonso Quintas-Cardama, MD, Ayalew Tefferi, M.D., Jorge Cortes, M.D., Animesh Pardanani, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Pat Ault, R.N., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4902.

https://doi.org/10.1182/blood.V108.11.4902.4902

Published: 2006

Journal Articles

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

Gerard Lozanski, MD, Ben Sanford, MS, Daohai Yu, PhD, Rebecca Pearson, MLT, Colin Edwards, MS, John C. Byrd, MD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Wendy Stock, MD

Blood (2006) 108 (11): 2293.

https://doi.org/10.1182/blood.V108.11.2293.2293

Published: 2006

Journal Articles

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Mohammad R. Rezvany, Mahmood J. Tehrani, Claes Karlsson, Jeanette Lundin, Hodjattallah Rabbani, Håkan Mellstedt, Anders Österborg

Blood (2005) 106 (11): 2986.

https://doi.org/10.1182/blood.V106.11.2986.2986

Published: 2005

Journal Articles

Population Pharmacokinetics of Alemtuzumab in Patients with Hematologic Malignancies.

Peter L. Bonate, Michael Keating, Steve Weitman, Peter Hillmen, Diane R. Mould

Blood (2005) 106 (11): 2961.

https://doi.org/10.1182/blood.V106.11.2961.2961

Published: 2005

NARROW

Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia

A Polyclonal Population of Piga Mutant CD52 and GPI Anchor Negative T Cells Can Give Early Immune Protection after Alemtuzumab-Based T Cell Depleted Allogeneic Stem Cell Transplantation

Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants

Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).

Sustained, Durable Responses with Alemtuzumab in Refractory Angioimmunoblastic T-Cell Lymphoma.

Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.

Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada

Alemtuzumab and DHAP (A-DHAP) Is An Effective Salvage Therapy for Peripheral T-Cell Lymphoma, Unspecified: Interim Results of a Phase II Prospective Multicenter Study

Emergence of Rituximab-Fludarabine Resistance Is Associated with Changes in CD20 Antigen Expression and Improved Response to Almetuzumab Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102).

Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft- Versus -Host Disease.

A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD).

Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Population Pharmacokinetics of Alemtuzumab in Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only